Bimatoprost

also known as Lumigan · "Lumigan" is the branded name of bimatoprost in eye drop form · Bimatoprost SR · Durysta · T4032 · AGN 192024 · BIM · Bimatoprost 0.03% solution (Lumigan) · +13 more

Other / unclassified targets PTGFR via activation

Developed for: ocular hypertension · glaucoma · open-angle glaucoma · hypotrichosis · cataract · hypotrichosis of eyelid · androgenetic alopecia · baldness, male pattern
+15 more
· disease of orbital part of eye adnexa · low tension glaucoma · vitiligo · alopecia · alopecia areata · alopecia, isolated · borderline glaucoma · endocrine exophthalmos · eyelid disorder · generalized vitiligo · hypopigmentation of the skin · migraine disorder · reactive cutaneous fibrous lesion · chronic closed-angle glaucoma · hypertrichosis
Investigated by: Allergan · ForSight Vision5, Inc. · AbbVie · SpyGlass Pharma, Inc. · Innovative Medical · Laboratoires Thea
+39 more
· University of Miami · ATS Clinical Research · Afyon Kocatepe University Hospital · Ahmed Hassan Nouh MD · Alcon Research · Assiut University · Association for Innovation and Biomedical Research on Light and Image · Canadian Glaucoma Clinical Research Council · Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Credit Valley EyeCare · Duke University · European Vision Institute Clinical Research Network · Federal University of São Paulo · Gian Sagar Medical College and Hospital · Indiana University · Johns Hopkins University · Jonsson Comprehensive Cancer Center · Julie Dawson · Kenneth Beer · Larissa University Hospital · Latham Fund · Manistee Partners · MediPrint Ophthalmics, Inc. · Medical University of South Carolina · Medstar Health Research Institute · Ministry of Health, Malaysia · National Eye Institute (NEI) · Northwestern University · Pharmaceutical Research Network · Rabin Medical Center · Robin, Alan L., M.D. · Salus University · Southern College of Optometry · Stanford University · Tulane University · Universitaire Ziekenhuizen KU Leuven · University of California, San Diego · University of Campinas, Brazil · University of Milan

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed glaucoma 1, open angle, P 1 milestone
Filed	US (FDA)	—	glaucoma 1, open angle, P	2019-07-17	“today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the company's New Drug Application (NDA) for Bimatoprost Sustained-Release (SR).” abbvie.com ↗
Approved Indication not stated 4 milestones
Label expansion	US (FDA)	LATISSE	—	2014-09-04	fda.gov ↗
Label expansion	US (FDA)	LUMIGAN	—	2006-06-22	fda.gov ↗
Approved	EU (EMA)	Lumigan	—	2002-03-08	europa.eu ↗
Approved	US (FDA)	LUMIGAN	—	2001-03-16	fda.gov ↗

Trials 101 · started per year

today

US approved 2001

EU approved 2002

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT04738149	Nov 2021 → May 2022	vitiligo	Medical University of South Carolina	Completed	No outcome recorded
Phase 0	NCT03708627	Nov 2017 → Jul 2029 expected	disease of orbital part of eye adnexa	Johns Hopkins University	Recruiting	No outcome recorded
Phase 0	NCT02830776	Nov 2016 → Apr 2017	eyelid disorder	Tulane University	Completed	No outcome recorded
Phase 16 trials
Phase 1	NCT07641296	Jul 2026 → Feb 2027 expected	glaucoma, ocular hypertension	SpyGlass Pharma, Inc.	Not yet recruiting	No outcome recorded
Phase 1	NCT05729594	Feb → Apr 2023	—	Laboratoires Thea	Completed	No outcome recorded
Phase 1	NCT02848300	Jul → Oct 2016	androgenetic alopecia	Allergan	Completed	No outcome recorded
Phase 1	NCT02676310	Mar 2016 → Jan 2017	androgenetic alopecia	Allergan	Terminated	No outcome recorded
Phase 1	NCT02444767	Mar → Apr 2015	—	ForSight Vision5, Inc.	Completed	No outcome recorded
Phase 1	NCT01189279	Oct 2010 → Jan 2011	baldness, male pattern	Allergan	Completed	No outcome recorded
Phase 1/24 trials
Phase 1/2	NCT06120842	Oct 2023 → Jan 2025 overdue	cataract, glaucoma, ocular hypertension	SpyGlass Pharma, Inc.	Active not recruiting	No outcome recorded
Phase 1/2	NCT05600673	Jan 2019 → Jan 2021	alopecia areata	Ahmed Hassan Nouh MD	Completed	No outcome recorded
Phase 1/2	NCT02742649	Apr → Dec 2016	ocular hypertension, open-angle glaucoma	ForSight Vision5, Inc.	Completed	No outcome recorded
Phase 1/2	NCT01157364	Sep 2010 → Jul 2016	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 216 trials
Phase 2	NCT06122090	Jul 2023 → Dec 2024	hypopigmentation of the skin, reactive cutaneous fibrous lesion	Medstar Health Research Institute	Unknown	No outcome recorded
Phase 2	NCT04747808	Jan → Feb 2021	ocular hypertension, open-angle glaucoma	MediPrint Ophthalmics, Inc.	Completed	No outcome recorded
Phase 2	NCT03419715	Jan 2018 → Apr 2019	migraine disorder	Manistee Partners	Unknown	No outcome recorded
Phase 2	NCT03292796	Dec 2016 → Oct 2019	open-angle glaucoma	Julie Dawson	Completed	No outcome recorded
Phase 2	NCT02537015	Aug 2015 → Aug 2016	ocular hypertension, open-angle glaucoma	ForSight Vision5, Inc.	Completed	No outcome recorded
Phase 2	NCT02358369	Jan → Aug 2015	ocular hypertension, open-angle glaucoma	ForSight Vision5, Inc.	Completed	No outcome recorded
Phase 2	NCT02143843	Jun 2014 → Dec 2015	ocular hypertension, open-angle glaucoma	ForSight Vision5, Inc.	Completed	No outcome recorded
Phase 2	NCT01915940	Oct 2013 → Sep 2014	ocular hypertension, open-angle glaucoma	ForSight Vision5, Inc.	Completed	No outcome recorded
Phase 2	NCT01904721	Aug 2013 → Sep 2014	androgenetic alopecia	Allergan	Completed	No outcome recorded
Phase 2	NCT01325350	Jun 2011 → Jul 2012	androgenetic alopecia	Allergan	Completed	No outcome recorded
Phase 2	NCT01325337	Jun 2011 → Aug 2012	baldness, male pattern	Allergan	Completed	No outcome recorded
Phase 2	NCT01291108	Apr → Oct 2011	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 2	NCT01064882	Mar → Jul 2010	hypotrichosis of eyelid	Allergan	Completed	No outcome recorded
Phase 2	NCT00538304	Nov 2007 → May 2008	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 2	NCT00652496	Jan → May 2005	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 2	NCT00651859	Nov 2002 → Jan 2004	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT00300443	Dec 2005 → Jun 2007	ocular hypertension	Allergan	Completed	Mixed
Phase 331 trials · 7 met primary
Phase 3	NCT07218796	Oct 2025 → May 2029 expected	cataract, glaucoma, ocular hypertension	SpyGlass Pharma, Inc.	Recruiting	No outcome recorded
Phase 3	NCT07218783	Oct 2025 → Mar 2029 expected	cataract, ocular hypertension, open-angle glaucoma	SpyGlass Pharma, Inc.	Recruiting	No outcome recorded
Phase 3	NCT05397600	Jun 2022 → Mar 2024	glaucoma, ocular hypertension	Laboratoires Thea	Completed	No outcome recorded
Phase 3	NCT04898387	Mar 2021 → Apr 2023	ocular hypertension	Laboratoires Thea	Completed	No outcome recorded
Phase 3	NCT04285580	Jun 2020 → May 2022	ocular hypertension, open-angle glaucoma	AbbVie	Completed	No outcome recorded
Phase 3	NCT03891446	Mar 2019 → Jun 2026	ocular hypertension, open-angle glaucoma	AbbVie	Completed	No outcome recorded
Phase 3	NCT03850782	Feb 2019 → Aug 2025	ocular hypertension, open-angle glaucoma	AbbVie	Completed	No outcome recorded
Phase 3	NCT03825380	Nov 2018 → Feb 2021	glaucoma, ocular hypertension	Laboratoires Thea	Completed	No outcome recorded
Phase 3	NCT02636946	Feb 2016 → Jan 2021	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT02390284	Sep 2015 → Oct 2024	glaucoma	University of Miami	Terminated	No outcome recorded
Phase 3	NCT02507687	Aug 2015 → Nov 2021	ocular hypertension, open-angle glaucoma	AbbVie	Completed	Met primary
Phase 3	NCT02250651	Dec 2014 → Oct 2018	ocular hypertension, open-angle glaucoma	Allergan	Completed	Met primary
Phase 3	NCT02155049	Nov 2014 → May 2017	disease of orbital part of eye adnexa	Rabin Medical Center	Completed	No outcome recorded
Phase 3	NCT01830140	Jul 2013 → May 2014	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT01765764	Mar 2013 → Jan 2014	hypotrichosis	Allergan	Completed	No outcome recorded
Phase 3	NCT01698554	Nov 2012 → Feb 2014	hypotrichosis of eyelid	Allergan	Completed	No outcome recorded
Phase 3	NCT01426113	Sep 2011 → Oct 2014	glaucoma	Allergan	Terminated	No outcome recorded
Phase 3	NCT01391273	Jul 2011 → May 2012	hypotrichosis of eyelid	Allergan	Completed	No outcome recorded
Phase 3	NCT01391286	Jul 2011 → May 2012	hypotrichosis of eyelid	Allergan	Completed	No outcome recorded
Phase 3	NCT01241240	Mar 2011 → Sep 2013	ocular hypertension, open-angle glaucoma	Allergan	Completed	Met primary
Phase 3	NCT01217606	Jan 2011 → Sep 2014	ocular hypertension, open-angle glaucoma	Allergan	Completed	Met primary
Phase 3	NCT01216943	Nov 2010 → Aug 2012	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT01168414	Aug 2010 → Jan 2011	ocular hypertension, open-angle glaucoma	Ministry of Health, Malaysia	Completed	No outcome recorded
Phase 3	NCT01099774	May 2010 → Apr 2011	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00907426	Aug 2009 → Nov 2010	hypotrichosis	Allergan	Completed	Met primary
Phase 3	NCT00693420	Apr → Oct 2007	—	Allergan	Completed	Met primary
Phase 3	NCT01200251	Feb → Sep 2007	alopecia, isolated, hypotrichosis	Duke University	Completed	No outcome recorded
Phase 3	NCT00332059	May 2003 → Sep 2004	ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00332072	Aug 2001 → Aug 2003	ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT00332540	Aug 2001 → Aug 2003	ocular hypertension	Allergan	Completed	No outcome recorded
Phase 3	NCT02154217	? → Dec 2004	glaucoma	University of Milan	Completed	Met primary

Phase 436 trials · 4 met primary
Phase 4	NCT07845357	Oct 2026 → Feb 2027 expected	dry eye syndrome, glaucoma	Southern College of Optometry	Not yet recruiting	No outcome recorded
Phase 4	NCT07217678	Feb 2026 → Jan 2028 expected	borderline glaucoma, ocular hypertension, open-angle glaucoma	University of Miami	Recruiting	No outcome recorded
Phase 4	NCT04981886	Aug 2021 → Jul 2022	low tension glaucoma	Salus University	Unknown	No outcome recorded
Phase 4	NCT06761313	Mar 2021 → Dec 2024 overdue	glaucoma	Federal University of São Paulo	Active not recruiting	No outcome recorded
Phase 4	NCT03487042	May 2018 → Dec 2019	generalized vitiligo	Assiut University	Unknown	No outcome recorded
Phase 4	NCT02863705	Jul 2016 → Jul 2018	low tension glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT02571712	Nov 2015 → Jun 2018	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT02471105	Sep 2015 → May 2017	glaucoma, ocular hypertension	Universitaire Ziekenhuizen KU Leuven	Unknown	Met primary
Phase 4	NCT02176356	Jun 2014 → May 2015	—	Allergan	Completed	No outcome recorded
Phase 4	NCT01927406	Jun 2014 → Dec 2016	endocrine exophthalmos, glaucoma, ocular hypertension	Stanford University	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT03966560	Jan 2014 → Jan 2015	open-angle glaucoma	Afyon Kocatepe University Hospital	Completed	No outcome recorded
Phase 4	NCT01975714	Oct 2013 → Feb 2015	glaucoma, ocular hypertension	Association for Innovation and Biomedical Research on Light and Image	Completed	No outcome recorded
Phase 4	NCT01891487	May 2013 → Sep 2014	hypotrichosis	ATS Clinical Research	Completed	No outcome recorded
Phase 4	NCT01594970	Mar 2012 → Jan 2013	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT01535768	Feb 2012 → Jun 2018	glaucoma	Credit Valley EyeCare	Unknown	No outcome recorded
Phase 4	NCT01978015	Oct 2011 → Jul 2012	anterior uveitis, cystoid macular edema	University of Campinas, Brazil	Completed	No outcome recorded
Phase 4	NCT01464424	Oct 2011 → Jun 2012	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	Met primary
Phase 4	NCT02020512	Jul 2011 → Dec 2012	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT01298700	May 2011 → Dec 2016	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT01387906	Mar 2011 → Mar 2012	hypotrichosis	Kenneth Beer	Completed	No outcome recorded
Phase 4	NCT01271686	Jan 2011 → Oct 2012	glaucoma, ocular hypertension	University of California, San Diego	Completed	Met primary
Phase 4	NCT01202513	Aug → Nov 2010	vitiligo	Gian Sagar Medical College and Hospital	Withdrawn	No outcome recorded
Phase 4	NCT02061683	Apr 2010 → Jun 2011	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT01833741	Dec 2009 → Mar 2011	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT00958035	Nov 2009 → Jul 2010	hypotrichosis	Allergan	Completed	No outcome recorded
Phase 4	NCT01229423	Nov 2009 → Jun 2010	hypotrichosis of eyelid	Allergan	Completed	No outcome recorded
Phase 4	NCT00941096	Jul 2009 → Nov 2010	glaucoma, ocular hypertension	Larissa University Hospital	Completed	No outcome recorded
Phase 4	NCT00539526	Sep 2007 → Jul 2008	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT00440011	Aug 2006 → Oct 2007	glaucoma, ocular hypertension	Allergan	Completed	Met primary
Phase 4	NCT00273455	Jan 2006 → May 2007	open-angle glaucoma	Pharmaceutical Research Network	Completed	No outcome recorded
Phase 4	NCT00329095	Dec 2005 → Apr 2006	glaucoma, ocular hypertension	Robin, Alan L., M.D.	Completed	No outcome recorded
Phase 4	NCT00355446	Jul 2001 → Oct 2004	cataract	Indiana University	Completed	No outcome recorded
Phase 4	NCT00348062	—	glaucoma	Innovative Medical	Completed	No outcome recorded
Phase 4	NCT00347802	—	glaucoma	Innovative Medical	Completed	No outcome recorded
Phase 4	NCT00347841	—	glaucoma	Innovative Medical	Completed	No outcome recorded
Phase 4	NCT00348023	—	glaucoma	Innovative Medical	Completed	No outcome recorded

Phase not applicable4 trials · 1 met primary · 1 missed
—	NCT07154797	Apr → Dec 2022	cataract, glaucoma, ocular hypertension	SpyGlass Pharma, Inc.	Completed	Met primary
—	NCT00999557	Jan 2016 → Aug 2017	alopecia, breast cancer	Jonsson Comprehensive Cancer Center	Withdrawn	No outcome recorded
—	NCT02448043	Jun 2015 → May 2016	ocular hypertension	Northwestern University	Completed	Missed primary
—	NCT01361841	Jan 2009 → Jan 2012	ocular hypertension, open-angle glaucoma	Centre de recherche du Centre hospitalier universitaire de Sherbrooke	Unknown	No outcome recorded
Comparator or background therapy39 trials
Phase 1/2	NCT00809848 Comparator	Feb → May 2009	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 2	NCT05335122 Comparator	Mar 2022 → Jan 2024	ocular hypertension, open-angle glaucoma	Ocular Therapeutix, Inc.	Completed	No outcome recorded
Phase 2	NCT01863953 Comparator	Jun → Dec 2013	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 2	NCT01110499 Comparator	Jun 2010 → May 2011	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 2	NCT01001195 Comparator	Nov 2009 → Apr 2010	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 2	NCT02170662 Comparator	Nov 2009 → May 2011	baldness, male pattern	Duke University	Completed	No outcome recorded
Phase 2	NCT01016691 Background	Oct 2009 → Feb 2010	ocular hypertension, open-angle glaucoma	Vistakon Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT07661329 Comparator	Jun 2026 → Nov 2027 expected	ocular hypertension, open-angle glaucoma	YS Life Science Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT03927443 Comparator	Jun → Jul 2019	ocular hypertension, open-angle glaucoma	Sun Pharmaceutical Industries, Inc.	Withdrawn	No outcome recorded
Phase 3	NCT03284853 Comparator	Sep 2017 → Nov 2020	ocular hypertension, open-angle glaucoma	Aerie Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01177098 Comparator	Oct 2010 → Feb 2012	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT06369077 Comparator	Apr → Jul 2024	open-angle glaucoma	CT Glaucoma Associates	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT02419508 Background	Aug 2015 → Feb 2018	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	Met primary
Phase 4	NCT02059655 Comparator	Nov 2014 → Mar 2016	disease of orbital part of eye adnexa	Cardiff University	Completed	No outcome recorded
Phase 4	NCT02097719 Comparator	May → Dec 2014	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT02017327 Comparator	Dec 2013 → Jul 2016	ocular hypertension, open-angle glaucoma	Laboratoires Thea	Completed	No outcome recorded
Phase 4	NCT01937312 Background	Oct 2013 → May 2014	ocular hypertension, open-angle glaucoma	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01881126 Comparator	Jun 2013 → Oct 2014	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT01664039 Comparator	Sep 2012 → Jun 2014	glaucoma, ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01525173 Comparator	Jan → Oct 2012	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT01547598 Comparator	Dec 2011 → Jul 2013	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT01448525 Comparator	Oct 2011 → Apr 2012	hypotrichosis	Allergan	Completed	No outcome recorded
Phase 4	NCT01263444 Background	Mar 2011 → Apr 2013	glaucoma, ocular hypertension	Alcon Research	Completed	No outcome recorded
Phase 4	NCT01253902 Comparator	Dec 2010 → Oct 2011	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT01243567 Comparator	Jun 2010 → Feb 2012	open-angle glaucoma	Allergan	Completed	No outcome recorded
Phase 4	NCT01023841 Comparator	Jun 2010 → Nov 2012	alopecia areata, hypotrichosis of eyelid	Allergan	Completed	No outcome recorded
Phase 4	NCT01448837 Comparator	Apr 2010 → Mar 2011	glaucoma	Aristotle University Of Thessaloniki	Completed	No outcome recorded
Phase 4	NCT01170884 Comparator	Dec 2009 → Sep 2010	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00705757 Comparator	Mar 2008 → Apr 2011	glaucoma, hyperpigmentation of the skin	Summa Health System	Completed	No outcome recorded
Phase 4	NCT00541242 Comparator	Dec 2007 → Aug 2008	glaucoma, ocular hypertension	Allergan	Completed	No outcome recorded
Phase 4	NCT00847483 Comparator	Jan → Aug 2002	glaucoma, ocular hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT01655758 Comparator	Jan 2002 → Dec 2003	ocular hypertension	University of Parma	Completed	No outcome recorded
—	NCT05241938 Comparator	Sep 2021 → Dec 2022	ocular hypertension, open-angle glaucoma	Federal University of Rio Grande do Sul	Unknown	No outcome recorded
—	NCT02774811 Comparator	Feb 2014 → Jan 2019	glaucoma	University College, London	Terminated	No outcome recorded
—	NCT01068964 Comparator	Feb → Sep 2010	ocular hypertension, open-angle glaucoma	Allergan	Completed	No outcome recorded
—	NCT00773136 Comparator	Feb → Jul 2008	hypertrichosis	University of Miami	Completed	No outcome recorded
—	NCT00567788 Comparator	Jul 2006 → Jul 2008	chronic closed-angle glaucoma	Singapore National Eye Centre	Unknown	No outcome recorded
—	NCT00187577 Comparator	Jun 2005 → Feb 2006	alopecia areata	University of California, San Francisco	Completed	No outcome recorded
—	NCT05338606 Background	—	open-angle glaucoma	AbbVie	No longer available	No outcome recorded

News releases announcing trial results or a regulatory action · 6

Date	Issuer	Release
2026-03-09	SpyGlass Pharma, Inc.	Results SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System spyglasspharma.com ↗ 98% of evaluable patients (48 of 49) in the 78-mcg dose group and 96% of evaluable patients (22 of 23) in the 39-mcg dose group were free from all topical IOP-lowering medications.
2025-09-23	Impax Laboratories, LLC	Regulatory Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% amneal.com ↗ Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL).
2023-12-14	NicOx Inc.	Results Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan nicox.com ↗ The publication “ NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non -Human Primates and Human Trabecular Meshwork/Schlemm’s Canal Constructs” by Galli et al. is available by clicking here.
2023-07-26	Impax Laboratories, LLC	Regulatory Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics amneal.com ↗ Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has submitted Abbreviated New Drug Applications (“ANDA”) to the U.S. Food and Drug Administration (FDA) for three key complex generic products, including:
2019-04-01	Alembic Pharmaceuticals Ltd.	Regulatory 15th April, 2019, Vadodara, India alembicpharmaceuticals.com ↗ Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bimatoprost Ophthalmic Solution, 0.03%.
2015-02-23	Lupin Limited	Regulatory Lupin Receives US FDA Approval for Generic Lumigan® Ophthalmic Solution 0.03%. lupin.com ↗

All press releases naming this drug 13 releases

Date	Issuer	Release
2026-04-09	Impax Laboratories, LLC	Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% amneal.com ↗
2026-03-09	SpyGlass Pharma, Inc.	SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System spyglasspharma.com ↗
2025-09-23	Impax Laboratories, LLC	Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% amneal.com ↗
2023-12-14	NicOx Inc.	Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan nicox.com ↗
2023-07-26	Impax Laboratories, LLC	Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics amneal.com ↗
2020-02-25	AbbVie	Allergan to Present New Data for Investigational Bimatoprost Sustained-Release at American Glaucoma Society Annual Meeting abbvie.com ↗
2019-07-17	AbbVie	U.S. FDA Accepts Allergan's New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension abbvie.com ↗
2019-05-03	AbbVie	Allergan to Present Two Podium Presentations on Bimatoprost Sustained-Release (SR) at The American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting abbvie.com ↗
2019-04-01	Alembic Pharmaceuticals Ltd.	15th April, 2019, Vadodara, India alembicpharmaceuticals.com ↗
2019-03-14	AbbVie	Allergan to Present New Data - "Extended Duration of Intraocular Pressure (IOP) Control with Intracameral Bimatoprost Sustained-Release (SR) Implant" -- Highlighting Clinical Advances at the American Glaucoma Society Annual Meeting abbvie.com ↗
2019-01-07	AbbVie	Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension abbvie.com ↗
2018-06-13	AbbVie	Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant for IOP Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension abbvie.com ↗
2015-02-23	Lupin Limited	Lupin Receives US FDA Approval for Generic Lumigan® Ophthalmic Solution 0.03%. lupin.com ↗

Evidence & citations 26 cited values

Every value below carries the sentence it was read from. 143 sources stand behind the page.

Field	Value	Cited text
Known as	bimatoprost	“a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs...” NCT01535768 ↗ 137 “prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye.” NCT01927406 ↗ “Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)” NCT01168414 ↗ “GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.” NCT03284853 ↗ “Prostaglandin analogue eye drops (latanoprost, bimatoprost or travoprost) will be prescribed” NCT05241938 ↗ “Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.” NCT02017327 ↗ “Compare also to timolol/brimonidine/dorzolamide/bimatoprost” NCT06369077 ↗ “Group 4 extended-wear contact lens printed with bimatoprost” NCT04747808 ↗ “Lumigan ® 0.01% (Bimatoprost Ophthalmic Solution)” NCT03927443 ↗ “LUMIGAN® (Bimatoprost ophthalmic solution, 0.01%)” NCT02419508 ↗ “Latanoprost Travaprost Bimatoprost Tafluprost” NCT03292796 ↗ Show 127 more sources
Known as	"Lumigan" is the branded name of bimatoprost in eye drop form	“"Lumigan" is the branded name of bimatoprost in eye drop form” NCT02537015 ↗ 1 “"Lumigan" is the branded name of bimatoprost in eye drop form” NCT02143843 ↗
Known as	AGN 192024	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200963 ↗
Known as	BIM	“BAK-free travoprost 0.004% (TRAV) and BAK 0.02%-preserved bimatoprost 0.01% (BIM) during late-day time points in patients with open-angle glaucoma or ocular hypertension.” PMID 25432143 ↗ Nov 2014
Known as	Bimatoprost 0.03% solution (Lumigan)	“Bimatoprost 0.03% solution (Lumigan)” NCT00187577 ↗
Known as	Bimatoprost component of ganfort	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200963 ↗
Known as	Bimatoprost Implant System	“Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL” NCT06120842 ↗
Known as	Bimatoprost SR	“Bimatoprost SR is a biodegradable, sustained-release, preservative-free bimatoprost implant, preloaded in an applicator for administration.” NCT02507687 ↗ 1 “received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study” NCT03891446 ↗
Known as	bimatoprost sustained-release (SR)	“This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension.” NCT02250651 ↗
Known as	BUDPF	“After the follow-up visit, patient will start Preservative-free bimatoprost 0.03% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months.” NCT01975714 ↗
Known as	Durysta	“Participants in this arm will receive a one-time injection of Durysta (intracameral bimatoprost 10mcg).” NCT07217678 ↗ 1 “Durysta, Bimatoprost Intracameral Implant 10 µg” NCT05335122 ↗
Known as	DurystaTM	“Currently, Bimatoprost SR (DurystaTM) from Allergan plc is the only FDA-approved SR therapy for POAG.” PMID 35076329 ↗ Dec 2022
Known as	Latisse	“Bimatoprost 0.03% ophthalmic solution is currently approved by the FDA for treatment of glaucoma (Lumigan™) and for thickening of thin eyelashes (Latisse™).” NCT02170662 ↗
Known as	Lumigan	“Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed” NCT02863705 ↗ 9 “Bimatoprost 0.03% ophthalmic solution is currently approved by the FDA for treatment of glaucoma (Lumigan™) and for thickening of thin eyelashes (Latisse™).” NCT02170662 ↗ “dosed with TRAVATAN Z®, XALATAN®, or LUMIGAN®, 1 drop instilled in each eye once daily for 28 days” NCT01937312 ↗ “bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.” NCT01110499 ↗ “Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year” NCT00705757 ↗ “Bimatoprost, aka Lumigan, one drop in one eye nightly” NCT03708627 ↗ “Bimatoprost (Lumigan) ophthalmic solution” NCT00187577 ↗ “bimatoprost = Lumigan®” NCT00541242 ↗ NCT03927443 ↗ NCT04285580 ↗
Known as	LUMIGAN (Bimatoprost ophthalmic solution, 0.01%)	“LUMIGAN® (Bimatoprost ophthalmic solution, 0.01%)” NCT02419508 ↗
Known as	Lumigan 0.01%	“Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.” NCT02017327 ↗
Known as	Lumigan 0.03% Unit Dose	“Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.” NCT02017327 ↗
Known as	LUMIGAN RC	“Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.” NCT01833741 ↗
Known as	Lumigan TM	“Three of these are commonly used in North America: latanoprost (Latanoprost T, Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).” NCT01361841 ↗
Known as	Prostamide	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200963 ↗
Known as	T4032	“Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients” NCT05397600 ↗ 1 “Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers” NCT05729594 ↗
Known as	ZOLYMBUS	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07845357 ↗
Action	Activate	“Prostanoid FP receptor agonist” CHEMBL1200963 ↗
Modality	Other / unclassified	“prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®)” NCT01253902 ↗
Route	Topical	“Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.” NCT00187577 ↗
Target	PTGFR	“Prostanoid FP receptor agonist” CHEMBL1200963 ↗